Bio Green Med Solution, formerly Cyclacel Pharmaceuticals, files regulatory reports that document a completed shift from a clinical-stage biopharmaceutical issuer to a diversified company engaged primarily in fire safety protection and distribution activities. The filings describe the acquisition of Fitters Sdn. Bhd., the liquidation of the former U.K. subsidiary, and the sale of the Plogosertib drug.
Its SEC record also includes Form 8-K disclosures on operating results, Regulation FD materials, quarterly cash dividend declarations on 6% Convertible Exchangeable Preferred Stock, Nasdaq listing-rule notices for the preferred stock, and proxy materials for annual-meeting governance and shareholder voting matters.
Bio Green Med Solution, Inc. reports that Nasdaq will delist its 6% Convertible Exchangeable Preferred Stock (symbol BGMSP) after the security failed to regain compliance with the $1 million minimum market value of publicly held shares requirement by March 10, 2026. Nasdaq notified the company on March 12, 2026, that trading in the preferred shares is expected to be suspended at the opening of business on March 23, 2026, with delisting expected on or after April 2, 2026. The company does not plan to appeal and believes the preferred stock may be quoted and traded on the OTC Markets after delisting. The company states that this action does not affect its common stock, which continues to trade on the Nasdaq Capital Market under the symbol BGMS.
Bio Green Med Solution, Inc. reports that Nasdaq will delist its 6% Convertible Exchangeable Preferred Stock (symbol BGMSP) after the security failed to regain compliance with the $1 million minimum market value of publicly held shares requirement by March 10, 2026. Nasdaq notified the company on March 12, 2026, that trading in the preferred shares is expected to be suspended at the opening of business on March 23, 2026, with delisting expected on or after April 2, 2026. The company does not plan to appeal and believes the preferred stock may be quoted and traded on the OTC Markets after delisting. The company states that this action does not affect its common stock, which continues to trade on the Nasdaq Capital Market under the symbol BGMS.
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., filed an amended current report to correct a presentation detail only. This Amendment No. 1 to the previously filed report updates the cover page to display the company’s correct new logo that aligns with its updated name and ticker symbol, as previously announced. The company states that no other changes have been made to the original report.
Kua Khai Loon, identified on the form as a Director, reported a sale of 19,054 shares of Cyclacel Pharmaceuticals common stock on 09/05/2025 at a price of $7.01 per share. After the reported transaction the filing shows 385,411 shares beneficially owned, held directly. The Form 4 is signed and dated 09/10/2025. The filing discloses the transaction type as a sale and provides the transaction price and post-transaction holdings; no derivative transactions or additional explanatory details are included.
Cyclacel Pharmaceuticals, Inc. reported that shareholders approved all proposals at a special meeting held on September 4, 2025. Investors backed the issuance of Cyclacel common stock to Fitters Parent under an Exchange Agreement, with 1,095,988 votes in favor and a reported 58.8% support level.
Shareholders also approved the potential issuance of more than 20% of the company’s outstanding common stock in connection with a transaction to comply with Nasdaq Listing Rule 5635(a), with similar voting support. In addition, they approved amending the certificate of incorporation to change the company’s name to Bio Green Med Solution, Inc., permit stockholder actions by written consent, ratify prior written-consent actions, and opt out of the business combination provisions of Section 203 of the Delaware General Corporation Law.
Cyclacel Pharmaceuticals, Inc. entered into a Warrant Exchange Agreement with certain accredited investors on September 4, 2025. The company agreed to exchange existing Series C common stock purchase warrants, which were exercisable for an aggregate of 559,395 shares of common stock, for an equal aggregate of 559,395 new shares of common stock issued directly to the holders.
The exchanged warrants were originally issued under a securities purchase agreement dated June 20, 2025. The new shares will be issued without registration under the Securities Act of 1933 in reliance on the Section 3(a)(9) exemption, meaning they are part of a private, unregistered exchange with existing security holders.
Yap Kim Choy, a director of Cyclacel Pharmaceuticals, Inc. (CYCC), exchanged Series C Common Stock Purchase Warrants for common shares on September 4, 2025. The reporting person exchanged 186,465 Series C warrants under a warrant exchange agreement dated September 4, 2025 and received 186,465 shares of Common Stock in return. After the transaction, the reporting person beneficially owned 404,465 shares of Common Stock and held 31,535 Series C warrants remaining. The filing is a Section 16 Form 4 reporting this non-derivative acquisition and related derivative changes.
Kua Khai Loon, a director of Cyclacel Pharmaceuticals, Inc. (ticker CYCC), reported on 09/04/2025 that he exchanged 186,465 Series C Common Stock Purchase Warrants for 186,465 shares of common stock under a warrant exchange agreement. After the transaction he beneficially owns 404,465 shares of common stock and directly holds 31,535 Series C warrants remaining. The filing indicates the exchange was recorded under transaction code J(1) and shows the warrants had a $10.20 conversion/exercise price and expire on 06/20/2030. This Form 4 documents the insider conversion of derivative securities into common equity.
Ong Yee Lung, a director of Cyclacel Pharmaceuticals, filed a Form 4 reporting that on 09/04/2025 he exchanged 186,465 Series C Common Stock Purchase Warrants for 186,465 shares of Common Stock pursuant to a warrant exchange agreement dated the same day. After the transaction, the reporting person beneficially owned 404,465 shares of Cyclacel common stock. The filing is signed and dated by the reporting person and indicates the change resulted from an exchange under the specified agreement.
Ong Yee Lung reports beneficial ownership of 20.76% of Cyclacel Pharmaceuticals, Inc.'s common stock class. The filing states he holds an aggregate of 872,000 instruments comprised of 218,000 common shares and three series of warrants — 218,000 Series A, 218,000 Series B and 218,000 Series C — each exercisable into common stock. The filing indicates sole voting and dispositive power over the aggregate amount and affirms the holdings were not acquired to change or influence control of the issuer.
Ong Yee Lung reports beneficial ownership of 20.76% of Cyclacel Pharmaceuticals, Inc.'s common stock class. The filing states he holds an aggregate of 872,000 instruments comprised of 218,000 common shares and three series of warrants — 218,000 Series A, 218,000 Series B and 218,000 Series C — each exercisable into common stock. The filing indicates sole voting and dispositive power over the aggregate amount and affirms the holdings were not acquired to change or influence control of the issuer.
Kua Khai Loon reports beneficial ownership of 872,000 shares of Cyclacel Pharmaceuticals, Inc., representing 20.76% of the outstanding common stock. The reported ownership is composed of 218,000 shares of common stock and 218,000 warrants in each of three series (Series A, B and C), each exercisable into common stock, for a total of 872,000 underlying shares. The filing certifies the holdings were not acquired to change or influence control of the issuer. The report includes links to the amended and restated warrant forms as exhibits.
Kua Khai Loon reports beneficial ownership of 872,000 shares of Cyclacel Pharmaceuticals, Inc., representing 20.76% of the outstanding common stock. The reported ownership is composed of 218,000 shares of common stock and 218,000 warrants in each of three series (Series A, B and C), each exercisable into common stock, for a total of 872,000 underlying shares. The filing certifies the holdings were not acquired to change or influence control of the issuer. The report includes links to the amended and restated warrant forms as exhibits.